Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Biotech
Alnylam abandons clinical-stage Type 2 diabetes asset
Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity.
Gabrielle Masson
Oct 31, 2024 10:27am
City Tx breaks ground with $135M, blueprints from Maraganore
Oct 8, 2024 10:38am
Arrowhead dips toes into obesity pond with 2 preclinical assets
Aug 14, 2024 3:50pm
Arrowhead RNAi med lowers triglycerides in phase 3
Jun 3, 2024 9:54am
Arrowhead's cholesterol drug hits the mark again in ph. 2 trial
May 28, 2024 9:13am
Arrowhead on target in lipid disorder as it pursues Ionis
Apr 8, 2024 9:37am
